

**AMENDMENTS TO THE CLAIMS**

*This listing of claims replaces all prior versions of listing of claims, and listing of claims in the application.*

1- 31 (Cancelled)

32. (Currently amended) A monomeric single-chain Fv (scFv) antibody fragment ~~comprising~~ consisting of an amino acid sequence as set forth in SEQ ID NO: 16, wherein the monomeric scFv antibody fragment is specific for human carcinoembryonic antigen.
33. (Previously presented) An antibody fragment according to claim 32, further comprising a detectable agent.
34. (Previously presented) An antibody fragment according to claim 33, wherein the detectable agent is a radioactive label.
35. (Previously presented) An antibody fragment according to claim 33, wherein the detectable agent is a reporter molecule.
36. (Currently amended) A pharmaceutical composition ~~comprising~~ consisting of an amino acid sequence as set forth in SEQ ID NO: 16 and a pharmaceutically-acceptable carrier.
37. (Canceled)
38. (Canceled)
39. (Currently amended) A divalent single-chain Fv (scFv) antibody fragment ~~comprising~~ consisting of an amino acid sequence as set forth in SEQ ID NO: 17, wherein the divalent scFv antibody fragment is specific for human carcinoembryonic antigen.

- 40. (Previously presented) An antibody fragment according to claim 38, further comprising a detectable agent.
- 41. (Previously presented) An antibody fragment according to claim 39, wherein the detectable agent is a radioactive label.
- 42. (Previously presented) An antibody fragment according to claim 39, wherein the detectable agent is a reporter molecule.
- 43. (Previously presented) A pharmaceutical composition comprising an amino acid sequence as set forth in SEQ ID NO: 17 and a pharmaceutically-acceptable carrier.
- 44. (Canceled)
- 45. (Canceled)
- 46. (Canceled)